Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average recommendation of “Hold” from the thirty ratings firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $33.68.

Several research firms have recently commented on SRPT. Bank of America lifted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a research report on Wednesday, October 22nd. Wells Fargo & Company cut their target price on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their price target for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. Wall Street Zen cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Piper Sandler boosted their price objective on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th.

Sarepta Therapeutics Trading Up 3.5%

Shares of SRPT opened at $22.31 on Wednesday. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $129.84. The firm has a market capitalization of $2.34 billion, a P/E ratio of -7.41 and a beta of 0.54. The firm has a 50-day moving average price of $20.88 and a 200 day moving average price of $20.64. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same period last year, the firm earned $0.62 earnings per share. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the stock. Allworth Financial LP raised its position in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Sarepta Therapeutics by 7.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 262,331 shares of the biotechnology company’s stock worth $5,055,000 after acquiring an additional 17,798 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Sarepta Therapeutics by 35.7% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 97,041 shares of the biotechnology company’s stock valued at $1,827,000 after acquiring an additional 25,508 shares during the period. PharVision Advisers LLC acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $357,000. Finally, Virtus Advisers LLC acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $497,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.